Hester Biosciences Sells Texas Lifesciences Stake for ₹92 Million

Hester Biosciences will sell a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for ₹92 million. The company's board approved the transaction on March 11, 2026.

Upon completion, TLPL will cease to be a subsidiary of Hester Biosciences, though Hester will retain an 11% minority stake. For the fiscal year ended March 31, 2025 (FY25), TLPL reported a turnover of ₹285.89 million and a net worth of ₹134.17 million. Hester Biosciences does not classify TLPL as a material subsidiary.

Background: Hester Biosciences and Texas Lifesciences

Hester Biosciences is a prominent Indian animal healthcare company known for its poultry and large animal vaccines, with operations in India and internationally.

Texas Lifesciences Private Limited, established in June 2017, manufactures chemical and pharmaceutical products, including formulations and capsules. A portion of its production is supplied to Hester Biosciences in India.

Strategic Rationale for the Sale

This divestment is seen as a strategic move allowing Hester Biosciences to focus more on its core animal health and vaccine businesses.

By exiting a non-core or non-material subsidiary, the company can potentially reallocate resources and capital to areas offering greater growth.

The sale will bring in ₹92 million in cash, which could be used for debt reduction, operational expansion, or other strategic initiatives.

Transaction Timeline

The transaction is expected to be finalized within three months from the agreement date of March 5, 2026.

Market Context and Risks

No specific risks related to this divestment were highlighted in the company's filing.

Hester Biosciences operates in a competitive animal healthcare market alongside major players such as Indian Immunologicals, Intas Pharmaceuticals, Vivaldis Animal Health, Zoetis, and Ceva.

What to Watch

Investors will be watching the completion of the share transfer process within the three-month timeframe.

They will also track how Hester Biosciences utilizes the capital raised from the sale and any future strategic implications for its core business segments.